Find the investors funding Health rounds
326,000+ VC, angel and family-office profiles — direct emails, check sizes and stage filters.
Former Mural Oncology CEO launches new cancer biotech with $225M in venture capital - The Business Journals
A new cancer biotech company has been launched by the former CEO of Mural Oncology. The company has secured $225 million in venture capital funding to advance its cancer research and development efforts.
Former Mural Oncology CEO launches new cancer biotech with $225M in venture capital The Business Journals
| Oct 09, 2026 | SpectaCell | $6.0M | Seed | Belgium |
| Oct 09, 2026 | Sava Technologies | $36.0M | Series B | United Kingdom |
| Oct 08, 2026 | Phantom GI | $5.0M | Seed | Israel |
| Oct 08, 2026 | Yazen | $60.4M | Late-stage | Sweden |
You just read who funded Mural Oncology. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.